LRRC37A2 Inhibitors

Inhibitors of LRRC37A2 such as Cycloheximide and rapamycin are inhibitors of protein biosynthesis, which can lead to a decrease in the overall levels of proteins within a cell, including LRRC37A2. By inhibiting specific kinases involved in signaling pathways, such as GSK-3 beta with lithium chloride, MEK with PD98059 and U0126, p38 MAPK with SB203580, JNK with SP600125, and PI3K with LY294002, the expression of LRRC37A2 can be affected as these pathways often regulate gene expression and protein stability.

Proteasome inhibitors like bortezomib and MG132 can prevent the degradation of proteins, potentially leading to an accumulation of LRRC37A2 if it is normally subject to proteasomal degradation. Ivermectin's influence on ion channels can alter neuronal function and signaling, which may have an impact on the expression or function of LRRC37A2 in neural cells. Lastly, retinoic acid is known to regulate gene expression, and thus it can alter the transcriptional levels of a wide array of proteins including LRRC37A2.